+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nanotechnology in Drug Delivery - Global Market Trajectory & Analytics

  • ID: 2769238
  • Report
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • AbbVie Inc.
  • BlueWillow Biologics
  • Celgene, Inc.
  • CYTIMMUNE SCIENCES, Inc.
  • EyePoint Pharmaceuticals
  • Nanobiotix
Global Nanotechnology in Drug Delivery Market to Reach $164.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Nanotechnology in Drug Delivery estimated at US$47.5 Billion in the year 2020, is projected to reach a revised size of US$164.1 Billion by 2027, growing at a CAGR of 19.4% over the period 2020-2027. Nanocrystals, one of the segments analyzed in the report, is projected to record 17.3% CAGR and reach US$83.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Nanocarriers segment is readjusted to a revised 21.9% CAGR for the next 7-year period.



The U.S. Market is Estimated at $12.8 Billion, While China is Forecast to Grow at 24.5% CAGR

The Nanotechnology in Drug Delivery market in the U.S. is estimated at US$12.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$38.8 Billion by the year 2027 trailing a CAGR of 24.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.2% and 17% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.2% CAGR.

Select Competitors (Total 43 Featured):
  • AbbVie Inc.
  • Aquanova AG
  • BlueWillow Biologics
  • Camurus AB
  • Celgene, Inc.
  • Ceramisphere Health Pty Limited
  • Cristal Therapeutics
  • CYTIMMUNE SCIENCES, Inc.
  • EnColl Corporation
  • EyePoint Pharmaceuticals
  • Lena Nanoceutics Ltd.
  • Nanobiotix
  • NanoCarrier Co., Ltd.
  • NanOlogy LLC
  • Nanospectra Biosciences, Inc.
  • Parvus Therapeutics Inc.
  • Selecta Biosciences
  • Starpharma Holdings Limited
  • Taiwan Liposome Co.,
  • Tarveda Therapeutics
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • BlueWillow Biologics
  • Celgene, Inc.
  • CYTIMMUNE SCIENCES, Inc.
  • EyePoint Pharmaceuticals
  • Nanobiotix
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Nanotechnology, A Critical Part of Healthcare Reform
  • Recent Market Activity
  • Nanomedicine, Revolutionizing the Basics of Medicine
  • A Peek Into the Evolving Role of Nanoparticles in Nanomedicine
  • Nanocrystals Continue to Gain Momentum as Alternatives to Traditional Nanocarriers
  • Nanocarriers Enable Targeted Drug Delivery Systems to Improve Therapeutic Outcomes
  • Advanced Liposomes Enable Low Soluble Drugs to Achieve Targeted Delivery
  • Multifunctional Dendrimers Present an Ideal Structure for Targeted Drug Delivery
  • High Drug Loading Capacity of PAMAM Dendrimers Bodes Well for Targeted Drug Delivery Systems
  • Nanotechnology-Based Strategies for siRNA Grows in Popularity
  • NEM Devices as Drug Delivery Vehicles
  • Nanotechnology - In Pursuit of Co-Delivery of Drugs
  • Nanoemulsions Begin to Make a Mark
  • Nanotechnology Finds Increasing Role in Fighting Infectious Diseases
  • List of Select Nanotechnology-based Antimicrobial Drugs in Clinical Use
  • Nanotechnology Opening New Avenues in Antiretroviral Therapy
  • Demonstrated Activity of Select Nanotechnology- Delivered Antiretroviral Therapies
  • Nanotechnology in Delivery of CNS Therapeutics
  • Market Outlook
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
  • AbbVie Inc. (USA)
  • Aquanova AG (Germany)
  • BlueWillow Biologics (USA)
  • Camurus AB (Sweden)
  • Celgene, Inc. (Canada)
  • Ceramisphere Health Pty Limited (Australia)
  • Cristal Therapeutics (The Netherlands)
  • CYTIMMUNE SCIENCES, INC. (Italy)
  • EnColl Corporation (USA)
  • EyePoint Pharmaceuticals (USA)
  • Lena Nanoceutics Ltd. (UK)
  • NanOlogy LLC (USA)
  • NanoCarrier Co., Ltd. (Japan)
  • Nanobiotix (France)
  • Nanospectra Biosciences, Inc (USA)
  • Parvus Therapeutics Inc. (USA)
  • Selecta Biosciences (USA)
  • Starpharma Holdings Limited (Australia)
  • Taiwan Liposome Co. (Taiwan)
  • Tarveda Therapeutics (USA)
3. MARKET TRENDS & DRIVERS
  • Growing Need for Alternative Approaches to Conventional Chemotherapy Creates Opportunities for Nanoparticles
  • Stimuli Responsive Polymeric Micelles Promise Enhanced Therapeutic Effect for Hydrophobic Anticancer Drugs
  • Inorganic Nanocarriers Facilitate High Payload Capacity and Co-Delivery Platforms for MDR Cancer Therapy
  • Solid Lipid Nanoparticles Provide Increased Physical Stability in Targeted Drug Delivery
  • Pulmonary Delivery of Nanoparticle-Based Drugs Receives Increased Interest
  • Inhalable Liposome Formulations Attract Research Interest in Pulmonary Delivery
  • SLNs in Pulmonary Delivery of Drugs
  • Market Challenges
  • Increasing Environmental and Health Concerns
  • Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement
  • Higher Concentration of Research in Academia limits Commercialization
  • Collaborations Assume Importance
  • Nanomedicine Regulation
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Nanotechnology in Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Nanotechnology in Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for Nanocrystals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for Nanocrystals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for Nanocarriers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for Nanocarriers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 7: USA Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 8: USA 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • CANADA
  • Table 9: Canada Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 10: Canada 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • JAPAN
  • Table 11: Japan Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 12: Japan 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • CHINA
  • Table 13: China Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 14: China 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • EUROPE
  • Table 15: Europe Current & Future Analysis for Nanotechnology in Drug Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 16: Europe 7-Year Perspective for Nanotechnology in Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020 & 2027
  • Table 17: Europe Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 18: Europe 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • FRANCE
  • Table 19: France Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: France 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • GERMANY
  • Table 21: Germany Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 22: Germany 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • ITALY
  • Table 23: Italy Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 24: Italy 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • UNITED KINGDOM
  • Table 25: UK Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: UK 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • SPAIN
  • Table 27: Spain Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 28: Spain 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • RUSSIA
  • Table 29: Russia Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 30: Russia 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • REST OF EUROPE
  • Table 31: Rest of Europe Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: Rest of Europe 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • ASIA-PACIFIC
  • Table 33: Asia-Pacific Current & Future Analysis for Nanotechnology in Drug Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 34: Asia-Pacific 7-Year Perspective for Nanotechnology in Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020 & 2027
  • Table 35: Asia-Pacific Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 36: Asia-Pacific 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • AUSTRALIA
  • Table 37: Australia Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Australia 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • INDIA
  • Table 39: India Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 40: India 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • SOUTH KOREA
  • Table 41: South Korea Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 42: South Korea 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • REST OF ASIA-PACIFIC
  • Table 43: Rest of Asia-Pacific Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Rest of Asia-Pacific 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • LATIN AMERICA
  • Table 45: Latin America Current & Future Analysis for Nanotechnology in Drug Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 46: Latin America 7-Year Perspective for Nanotechnology in Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020 & 2027
  • Table 47: Latin America Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 48: Latin America 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • ARGENTINA
  • Table 49: Argentina Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: Argentina 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • BRAZIL
  • Table 51: Brazil Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 52: Brazil 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • MEXICO
  • Table 53: Mexico Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 54: Mexico 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • REST OF LATIN AMERICA
  • Table 55: Rest of Latin America Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: Rest of Latin America 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • MIDDLE EAST
  • Table 57: Middle East Current & Future Analysis for Nanotechnology in Drug Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 58: Middle East 7-Year Perspective for Nanotechnology in Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020 & 2027
  • Table 59: Middle East Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 60: Middle East 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • IRAN
  • Table 61: Iran Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: Iran 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • ISRAEL
  • Table 63: Israel Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 64: Israel 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • SAUDI ARABIA
  • Table 65: Saudi Arabia Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 66: Saudi Arabia 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • UNITED ARAB EMIRATES
  • Table 67: UAE Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: UAE 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • REST OF MIDDLE EAST
  • Table 69: Rest of Middle East Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 70: Rest of Middle East 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
  • AFRICA
  • Table 71: Africa Current & Future Analysis for Nanotechnology in Drug Delivery by Technology - Nanocrystals and Nanocarriers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 72: Africa 7-Year Perspective for Nanotechnology in Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanocrystals and Nanocarriers for the Years 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 43
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Aquanova AG
  • BlueWillow Biologics
  • Camurus AB
  • Celgene, Inc.
  • Ceramisphere Health Pty Limited
  • Cristal Therapeutics
  • CYTIMMUNE SCIENCES, Inc.
  • EnColl Corporation
  • EyePoint Pharmaceuticals
  • Lena Nanoceutics Ltd.
  • Nanobiotix
  • NanoCarrier Co. Ltd.
  • NanOlogy LLC
  • Nanospectra Biosciences, Inc.
  • Parvus Therapeutics Inc.
  • Selecta Biosciences
  • Starpharma Holdings Limited
  • Taiwan Liposome Co.
  • Tarveda Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll